Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Офтальмология / Английские материалы / Retinal Degenerative Diseases Laboratory and Therapeutic Investigations_Anderson_2008.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
10.55 Mб
Скачать

Chapter 64

Protection of Photoreceptors in a Mouse Model

of RP10

Lawrence C. S. Tam, Anna-Sophia Kiang, Naomi Chadderton, Paul F. Kenna, Matthew Campbell, Marian M. Humphries, G. Jane Farrar,

and Pete Humphries

Abstract Recombinant adeno-associated viral (rAAV) vectors have recently been widely used for the delivery of therapeutic transgenes in preclinical and clinical studies for inherited retinal degenerative diseases. Interchanging capsid genes between different AAV serotypes has enabled selective delivery of transgene into specific cell type(s) of the retina. The RP10 form of autosomal dominant retinitis pigmentosa (adRP) is caused by missense mutations within the gene encoding inosine 5 -monophosphate dehydrogenase type 1. Here, we report that the use of rAAV2/5 vectors expressing shRNA targeting mutant IMPDH1 prevents photoreceptor degeneration, and preserves synaptic connectivity in a mouse model of RP10.

64.1 Introduction

Over the past decade, tremendous progress has been made in the field of therapeutic gene-based strategies for acquired and inherited ocular diseases. In particular, the commencement of three clinical trials in the United Kingdom and the United States for the autosomal recessive retinal dystrophy, Leber congenital amaurosis (LCA), has transcended the field of gene-mediated therapy for retinal diseases (Bainbridge et al. 2008; Maguire et al. 2008; Hauswirth et al. 2008). The advance from proofof principle study into human clinical trials has been made possible by extensive efforts placed in tackling one of the major obstacles in retinal gene therapy, namely to achieve specific, high level and long-term expression of therapeutic transgenes in the affected cell type(s). However, this has been made exceptionally difficult by the fact that the retina is composed of a complex arrangement of different cell types that are intricately networked together. In addition, the target tissues to which the therapy must be delivered depends on the disease. For example, recessively inherited retinal diseases such as LCA would require a gene replacement strategy focusing

L.C.S. Tam (B)

The Ocular Genetics Unit, Department of Genetics, Trinity College Dublin, Dublin 2, Ireland e-mail: lawrenct@tcd.ie

R.E. Anderson et al. (eds.), Retinal Degenerative Diseases, Advances in Experimental

559

Medicine and Biology 664, DOI 10.1007/978-1-4419-1399-9_64,C Springer Science+Business Media, LLC 2010